Importing Generic Medicines from India to Australia: Navigating the TGA Framework

Understanding the Australian Market for Indian Generics

Australia is a highly regulated, quality-focused market. Medicines are controlled by the Therapeutic Goods Administration (TGA), which operates under the Therapeutic Goods Act 1989. For importers and distributors, the opportunity is real: generic substitution is well established, and public funding through the Pharmaceutical Benefits Scheme (PBS) rewards competitive supply. But the pathway is structured, and a product cannot simply be shipped and sold. This guide explains the framework in practical terms so you can plan sourcing from India with realistic expectations.

Regulatory requirements change, so always confirm current rules directly with the TGA before committing to a product or shipment.

The Core Rule: Products Must Be on the ARTG

In general, therapeutic goods supplied in Australia must be entered on the Australian Register of Therapeutic Goods (ARTG). Prescription generics are typically assessed as registered medicines, and the application is built around a quality, safety and efficacy dossier, with bioequivalence evidence for most oral solid generics. Only after ARTG entry can the product be lawfully supplied in the ordinary commercial channel.

There are limited exceptions, such as access schemes for individual patients, which are not a basis for building a commercial generic business. If you are an importer, plan on the standard registration route.

The Role of the Australian Sponsor

A central concept in the TGA framework is the sponsor. A sponsor must be an entity based in Australia, and it is the sponsor that holds responsibility for the product on the ARTG. In practice the sponsor:

• Submits the application and maintains the ARTG entry
• Is accountable for product quality, complaints and recalls
• Manages pharmacovigilance and adverse event reporting
• Ensures labelling and product information remain compliant

An overseas manufacturer or exporter cannot act as the sponsor directly. Typically an Australian importer or distributor takes this role, supported by a supply partner in India that provides the technical documentation. Deciding who will be the sponsor is the first commercial decision to make.

Manufacturing Quality Evidence

The TGA expects every manufacturing site, including overseas sites, to meet Australian standards of Good Manufacturing Practice. For overseas facilities, the TGA relies on either its own inspection or acceptable evidence from comparable regulators or inspection schemes. The acceptable evidence depends on the site and country, so it is important to check what the TGA will accept for the specific Indian facility concerned.

Tuli Enterprise works with GMP-certified manufacturing partners and supports buyers with quality documentation. As a merchant exporter, we do not hold manufacturing certifications ourselves; these belong to the partner facilities. Ask early about inspection history, site master information and the product scope covered at the plant, since this often determines whether registration can proceed smoothly.

Typical Documents for a Registration Dossier

Australian applications generally follow the Common Technical Document (CTD) structure. Your Indian supplier should be able to provide, or help compile, the following:

• CTD dossier: Modules covering administrative information, quality, and, as relevant, nonclinical and clinical or bioequivalence data
• Certificate of Analysis (CoA): Batch-specific results against approved specifications
• Stability data: Long-term and accelerated studies supporting the proposed shelf life and storage conditions
• Certificate of Pharmaceutical Product (COPP): Issued by the Indian regulator, supporting the product's status in the country of manufacture
• Free Sale Certificate: Confirming the product is freely sold in India
• Manufacturing site information: Evidence of GMP compliance and site details
• Method validation and API information: Including source and specification of the active ingredient

Tuli Enterprise can provide COPP, CoA, CTD dossiers, Free Sale Certificates and stability data for products from our partner network. Whether a given dossier meets TGA expectations for a particular molecule should be confirmed with your regulatory consultant or the TGA.

Labelling and Packaging

Australian labels must meet national labelling standards, which set requirements for prominence, active ingredient names, strength, storage statements, and other mandatory information. Consumer Medicine Information and Product Information documents are also expected for many prescription products. Key practical points:

• Use English-language labelling with Australian-approved ingredient names
• Confirm pack sizes align with how the product is dispensed locally
• Plan artwork approval before commercial printing, not after
• Check any serialisation or barcode needs with your distribution partners

Packaging and artwork decisions are far easier to make before manufacture. If you need custom presentations, our contract manufacturing service allows pack design to be agreed upfront with the production partner.

Import Logistics and Compliance

Once a product is on the ARTG, imports still need proper handling. Border clearance requires accurate documentation, and importers should be aware of any licensing or permit conditions that apply to specific product types. The Australian sponsor or its licensed wholesaler must also handle storage and distribution under appropriate licensing. Temperature control, batch traceability and clear shipping documents help avoid delays at the border.

For commercial planning, remember that registration is typically the longest step. Lead times for manufacture are usually shorter and more predictable than the regulatory timeline, which depends on dossier readiness and TGA assessment. Avoid committing to launch dates until the regulatory path for each product is understood.

How to Select Products Wisely

Not every molecule is equally attractive. Consider the following when building a portfolio:

1. Market gap: Look for products with limited local competition or supply constraints
2. Dossier complexity: Oral solids with established reference products are generally simpler than complex formulations
3. PBS context: Pricing pressure is significant, so costs must be realistic
4. Supplier depth: Prefer partners with strong documentation and stable API sourcing

You can explore available molecules in our product catalogue and browse by therapeutic category to identify candidates that suit your portfolio. For broader context on how we support regulated and semi-regulated markets, see our countries we serve page.

MOQ, Lead Time and Samples

Minimum order quantities depend on the product, dosage form and packaging. Registration batches and commercial batches are usually planned separately, and the first supply is often smaller. Lead times vary by product and manufacturing slot, so request a written estimate rather than relying on general figures. Product samples and documentation packages can often be arranged for evaluation before a formal commitment, subject to the product and regulatory status.

Practical Checklist Before You Start

• Identify your Australian sponsor entity and its capabilities
• Shortlist molecules and confirm reference product details
• Request the dossier index, stability summary and site information
• Confirm GMP evidence acceptable to the TGA for the manufacturing site
• Agree artwork and pack formats early
• Confirm current TGA requirements before filing

For more regulatory explainers, visit our insights library.

Start a Conversation with Tuli Enterprise

Tuli Enterprise is a New Delhi-based merchant exporter supplying pharmaceuticals to over 95 countries and a member of PHARMEXCIL and FPME. If you are evaluating Indian generics for Australia, share your target molecules, strengths and volumes through our contact form, message us on WhatsApp at wa.me/919654308142, or email [email protected]. We will respond with documentation availability and a structured quotation.